Biorestorative Therapies (BRTX) to Release Earnings on Thursday

Biorestorative Therapies (NASDAQ:BRTX) is expected to post its Q4 2025 results after the market closes on Thursday, March 26th. Analysts expect Biorestorative Therapies to post earnings of ($0.37) per share and revenue of $0.15 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, April 3, 2026 at 9:30 AM ET.

Biorestorative Therapies Trading Up 16.8%

Shares of BRTX stock opened at $0.33 on Tuesday. The firm has a market capitalization of $2.96 million, a price-to-earnings ratio of -0.22 and a beta of 0.47. The business’s 50-day moving average price is $0.61 and its 200-day moving average price is $1.09. Biorestorative Therapies has a 12 month low of $0.19 and a 12 month high of $2.10.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Biorestorative Therapies currently has an average rating of “Sell”.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of BRTX. Virtu Financial LLC grew its stake in Biorestorative Therapies by 102.4% during the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after purchasing an additional 12,319 shares during the period. DRW Securities LLC acquired a new position in Biorestorative Therapies in the fourth quarter valued at approximately $55,000. Finally, Citadel Advisors LLC bought a new position in shares of Biorestorative Therapies during the 3rd quarter worth approximately $152,000. 69.38% of the stock is owned by institutional investors and hedge funds.

About Biorestorative Therapies

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.